Zobrazeno 1 - 10
of 52
pro vyhledávání: '"Navneet SINGH"'
Publikováno v:
Zootaxa. 5004:501-520
A new species, Pieris tadokoroi, sp. nov. is described from Himachal Pradesh, India. The new species is closely similar to those of the Pieris napi group and can be diagnosed by its smaller size and a broad apical forewing patch. Based on the recentl
Publikováno v:
Personalized Medicine. 18:333-346
Background: The study was carried out to evaluate the association of NQO1 P187S polymorphism in North Indian lung cancer (LC) patients. We determined the effect of this polymorphic variant on the survival of LC patients. Patients & methods/results: T
Publikováno v:
Oncologist
Background Irinotecan (CPT11) is an important drug for small cell lung cancer (SCLC) chemotherapy (CTx). UDP-glucuronosyltransferase 1A1 (UGT1A1) polymorphisms can influence CPT11-related toxicity. This study aimed to assess prevalence of UGT1A1 poly
Publikováno v:
Lung Cancer. 151:16-19
Objectives Epidermal Growth Factor Receptor (EGFR) and Anaplastic Lymphoma Kinase (ALK) Tyrosine Kinase Inhibitors (TKIs) are the preferred treatment option for patients with advanced/metastatic non-small cell lung cancer (NSCLC) harboring EGFR mutat
Autor:
John G. Edwards, Kari Chansky, Paul Van Schil, Andrew G. Nicholson, Souheil Boubia, Elisabeth Brambilla, Jessica Donington, Françoise Galateau-Sallé, Hans Hoffmann, Maurizio Infante, Mirella Marino, Edith M. Marom, Jun Nakajima, Marcin Ostrowski, William D. Travis, Ming-Sound Tsao, Yasushi Yatabe, Dorothy J. Giroux, Lynn Shemanski, John Crowley, Marc Krasnik, Hisao Asamura, Ramón Rami-Porta, Valerie Rusch, Luiz Henrique Araujo, David Beer, Pietro Bertoglio, Ricardo Beyruti, Andrea Bille, Vanessa Bolejack, James D. Brierley, A.K. Cangir, David Carbone, Gail Darling, Frank Detterbeck, Xavier Benoit D’Journo, Jessica Donnington, Wilfried Eberhardt, John Edwards, Jeremy Erasmus, Conrad Falkson, Wentao Fang, Dean Fennell, Kwun Fong, Françoise Galateau-Salle, Oliver Gautschi, Ritu Gill, Dorothy Giroux, Meredith Giuliani, Jin Mo Goo, Seiki Hasegawa, Fred Hirsch, Hans Hoffman, Wayne Hofstetter, James Huang, Philippe Joubert, Kemp Kernstine, Keith Kerr, Young Tae Kim, Hong Kwan Kim, Hedy Kindler, Yolande Lievens, Hui Liu, Donald E. Low, Gustavo Lyons, Heber MacMahon, Edith Marom, José-María Matilla, Jan van Meerbeeck, Luis M. Montuenga, Andrew Nicholson, Katie Nishimura, Anna Nowak, Isabelle Opitz, Meinoshin Okumura, Raymond U. Osarogiagbon, Harvey Pass, Marc de Perrot, Helmut Prosch, David Rice, Andreas Rimner, Enrico Ruffini, Shuji Sakai, Navneet Singh, Amy Stoll-D’Astice, Francisco Su´rez, Ricardo M. Terra, Ming S. Tsao, Paula Ugalde, David Waller, Shun-ichi Watanabe, Jacinta Wiens, Ignacio Wistuba, Liyan Jiang, Kaoru Kubota, Akif Turna, Benny Weksler, Maria Teresa Tzukazan, Martin Tammemägi, Charles Powell, David Naidich, Hongxu Liu, Samuel Armato, Alex Brunelli, Giuseppe Cardillo, Elizabeth David, Brigitte Fournier, Mark Krasnik, Kauro Kubota, Catherine Labbe, Eric Lim, Paul Martin Putora, Gaetano Rocco, Pier Luigi Filosso, Kazuya Kondo, Dong Kwan Kim, Giuseppe Giaccone, Marco Lucchi, Thomas Rice, Mark Ferguson, Prasad Adsusmilli, William Travis, Francisco Suárez, Kaura Kubota, Hisao Asamura Shun-ichi, Watanabe, Edith Marom Ramón, Rami-Porta, Ming Tsao, Ming Tsao Shun-ichi, Watanabe, Meredith Guiliani, James Brierley, Ricardo Terra, Ray Osarogiagbon, Luis Montuenga, Hongwei Wang, Françoise Galateau, Jim Mo Goo, Bill Travis, Jose Maria Matilla, Carolle St. Pierre, Ma Teresa Tzukazan, Nicholas Girard, Andreas Rimmer, Francoise Galateau, Prasad Adusumilli, Xavier D’Journo, Donald Low, Adam Rosenthal
Publikováno v:
Journal of theoretical biology
Journal of thoracic oncology
Journal of thoracic oncology
Objective: Our aim was to validate the prognostic relevance in NSCLC of potential residual tumor (R) descriptors, including the proposed International Association for the Study of Lung Cancer definition for uncertain resection, referred to as R(un).
Publikováno v:
Future Oncology. 15:151-165
Aim: The study investigates association of XPG polymorphism with lung cancer susceptibility, overall survival and clinical outcomes in North Indian population. Results: A significant protective effect was observed for 2228959 C/A polymorphism with lu
Autor:
Kakajan Komurov, Joo-Seop Park, Matthew T. Weirauch, Edith M. Janssen, Navneet Singh, Nathan Salomonis, Eunah Chung, Nancy Ratner, Kwangmin Choi, Lisa Privette-Vinnedge, Xiaoting Chen, Vishnu Modur, Susan E. Waltz, Gang Huang, Kashish Chetal, Vakul Mohanty, Belal A. Muhammad
Publikováno v:
Nature Communications, Vol 9, Iss 1, Pp 1-15 (2018)
Nature Communications
Nature Communications
The nature and role of global transcriptional deregulations in cancers are not fully understood. We report that a large proportion of cancers have widespread defects in mRNA transcription elongation (TE). Cancers with TE defects (TEdeff) display spur
Autor:
Nasser H. Hanna, Andrew G. Robinson, Sarah Temin, Sherman Baker, Julie R. Brahmer, Peter M. Ellis, Laurie E. Gaspar, Rami Y. Haddad, Paul J. Hesketh, Dharamvir Jain, Ishmael Jaiyesimi, David H. Johnson, Natasha B. Leighl, Pamela R. Moffitt, Tanyanika Phillips, Gregory J. Riely, Rafael Rosell, Joan H. Schiller, Bryan J. Schneider, Navneet Singh, David R. Spigel, Joan Tashbar, Gregory Masters
Publikováno v:
Journal of Clinical Oncology
r-IGTP. Repositorio Institucional de Producción Científica del Instituto de Investigación Germans Trias i Pujol
instname
r-IGTP. Repositorio Institucional de Producción Científica del Instituto de Investigación Germans Trias i Pujol
instname
PURPOSE To provide evidence-based recommendations updating the 2017 ASCO guideline on systemic therapy for patients with stage IV non–small-cell lung cancer (NSCLC) with driver alterations. A guideline update for systemic therapy for patients with
Publikováno v:
Current treatment options in oncology. 21(8)
Immune checkpoint inhibitors (ICIs) have revolutionized the management of metastatic and selected cases of unresectable advanced non-small cell lung cancer (NSCLC). Importantly for patients, this implies that in the absence of a targetable oncogenic
Autor:
Andrew G. Robinson, Rami Y. Haddad, Joan Tashbar, David R. Spigel, Nasser H. Hanna, Laurie E. Gaspar, Natasha B. Leighl, Julie R. Brahmer, Paul J. Hesketh, Sherman Baker, Peter M. Ellis, Navneet Singh, Gregory J. Riely, Rafael Rosell, Tanyanika Phillips, Ishmael Jaiyesimi, Sarah Temin, David H. Johnson, Joan H. Schiller, Dharamvir Jain, Janis O. Stabler, Gregory A. Masters, Bryan J. Schneider
Publikováno v:
Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 38(14)
PURPOSE The aim of this work is to provide evidence-based recommendations updating the 2017 ASCO guideline on systemic therapy for patients with stage IV non–small-cell lung cancer (NSCLC) without driver alterations. A guideline update for patients